Q3 2025 Sales Call November 4, 2025 9:00 AM ESTCompany ParticipantsHugues Chomel - Deputy Chief Executive Officer of ...
The ESSENCE trial was intended to prove the efficacy of Vyondys 53 (golodirsen) and Amondys 45 (casimersen), which received ...
Q3 2025 Earnings Call Transcript November 3, 2025 BioNTech SE misses on earnings expectations. Reported EPS is $-0.14 EPS, ...
Operator: Good morning, ladies and gentlemen, and welcome to the Cooper-Standard Third Quarter 2025 Earnings Conference Call.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback